These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 23151991)

  • 1. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
    Shah DK; Haddish-Berhane N; Betts A
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
    Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
    AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.
    Shah DK; King LE; Han X; Wentland JA; Zhang Y; Lucas J; Haddish-Berhane N; Betts A; Leal M
    AAPS J; 2014 May; 16(3):452-63. PubMed ID: 24578215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
    Ait-Oudhia S; Zhang W; Mager DE
    AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs).
    Scheuher B; Ghusinga KR; McGirr K; Nowak M; Panday S; Apgar J; Subramanian K; Betts A
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):429-447. PubMed ID: 37787918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
    Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
    Suri A; Mould DR; Song G; Kinley J; Venkatakrishnan K
    J Clin Pharmacol; 2020 Dec; 60(12):1585-1597. PubMed ID: 32596842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
    Singh AP; Shah DK
    AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
    Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ
    Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
    Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
    Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
    Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
    J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
    Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
    Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
    Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
    Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
    Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
    Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.